McKesson (MCK)
(Delayed Data from NYSE)
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$482.27 USD
-6.51 (-1.33%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $482.44 +0.17 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth C Momentum B VGM
Zacks News
Are Investors Undervaluing McKesson (MCK) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
McKesson (MCK) Beats on Q3 Earnings, Gains From Solid View
by Zacks Equity Research
McKesson (MCK) gains from the U.S. Pharmaceutical and Specialty Solutions segment in third-quarter fiscal 2019.
McKesson (MCK) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 6.92% and 1.69%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Lineup for Jan 31: EW, BAX & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few Medical Products bigwigs within the broader Medical space.
Will Core Business Units Boost McKesson's (MCK) Q3 Earnings?
by Zacks Equity Research
McKesson (MCK) expects to gain from solid segmental performances in third-quarter fiscal 2019.
Earnings Preview: McKesson (MCK) Q3 Earnings Expected to Decline
by Zacks Equity Research
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Investors Should Hold McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.
Genpact (G) Extends Multiyear Relationship With McKesson
by Zacks Equity Research
The relationship is based on a combination of Genpact's deep operations optimization experience and McKesson's operational excellence.
Here's Why You Should Hold on to Cerner (CERN) Stock for Now
by Zacks Equity Research
A bullish guidance for 2018 and a series of latest developments make Cerner (CERN) a promising investment pick.
Cerner (CERN) Collaborates With McKesson's CoverMyMeds
by Zacks Equity Research
Cerner's (CERN) ePrescribe workflow solution is likely to partner with CoverMyMeds' RxBenefit Clarity solution for prescription price transparency.
Is McKesson (MCK) a Great Stock for Value Investors?
by Zacks Equity Research
Let???s see if McKesson (MCK) stock is a good choice for value-oriented investors right now from multiple angles.
Rite Aid (RAD) Stock Up on Q3 Earnings Beat, FY19 View Down
by Zacks Equity Research
Rite Aid's (RAD) top and bottom lines improve year over year. Also, earnings came ahead of the Zacks Consensus Estimate but sales lagged the same.
Is McKesson (MCK) a Suitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if McKesson Corporation (MCK) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
BD Brings HealthSight Diversion App to Combat Opioid Crisis
by Zacks Equity Research
BD's (BDX) latest development is likely to boost the company's Medication Management unit.
McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
by Zacks Equity Research
McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.
McKesson (MCK) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Earnings Lineup for Oct 25: SYK, CERN & More
by Zacks Equity Research
Long-term potential of the Medical Products industry looks promising at the moment amid certain short-term geopolitical insecurities.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Core MedSurg Segment Aid Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
Stryker (SYK) is likely to gain from strong segmental performance in Q3; softness anticipated in Spine business.
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
McKesson (MCK) Q2 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
McKesson (MCK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Hold on to Allscripts (MDRX) Stock Now
by Zacks Equity Research
Strong prospects in Sunrise EHR platform to aid Allscripts (MDRX). However, intense competition in the MedTech space is a headwind.
NextGen Rides on Prospects in RCM Space, Competition Rife
by Zacks Equity Research
NextGen (NXGN) is a major player in the U.S. RCM market. However, the company faces cutthroat competition in the healthcare information systems and services market.
Quality Systems Ties Up With CoverMyMeds to Enable ePA
by Zacks Equity Research
Quality Systems' (QSII) new collaboration with CoverMyMeds sees bright market prospects.